2024
TARGET: A Randomized, Noninferiority Trial of a Pretest, Patient-Driven Genetic Education Webtool Versus Genetic Counseling for Prostate Cancer Germline Testing
Loeb S, Keith S, Cheng H, Leader A, Gross L, Nolasco T, Byrne N, Hartman R, Brown L, Pieczonka C, Gomella L, Kelly W, Lallas C, Handley N, Mille P, Mark J, Brown G, Chopra S, McClellan A, Wise D, Hollifield L, Giri V. TARGET: A Randomized, Noninferiority Trial of a Pretest, Patient-Driven Genetic Education Webtool Versus Genetic Counseling for Prostate Cancer Germline Testing. JCO Precision Oncology 2024, 8: e2300552. PMID: 38452310, PMCID: PMC10939575, DOI: 10.1200/po.23.00552.Peer-Reviewed Original ResearchConceptsGermline genetic testingDecisional conflictGenetic counselingProstate cancerPatient-drivenShortage of genetic counselorsKnowledge of cancer geneticsHereditary cancer riskReduce decisional conflictDecisional Conflict ScalePrimary outcome dataMixed-effects regression modelsDiverse patient populationsGenetic servicesClinical trial eligibilityGenetic counselorsGenetics educationPatient experienceCancer riskGermline testingAnalytical data setsCancer geneticsGermline evaluationConflict ScaleGenetic testing
2023
Technology-enhanced acceleration of germline evaluation for therapy (TARGET): Results of a randomized controlled trial of a pretest patient-driven webtool vs. genetic counseling for prostate cancer germline testing.
Giri V, Keith S, Cheng H, Leader A, Gross L, Sanchez Nolasco T, Byrne N, Hartman R, Brown L, Pieczonka C, Gomella L, Kelly W, Lallas C, Handley N, Mille P, Mark J, Brown G, Chopra S, McClellan A, Loeb S. Technology-enhanced acceleration of germline evaluation for therapy (TARGET): Results of a randomized controlled trial of a pretest patient-driven webtool vs. genetic counseling for prostate cancer germline testing. Journal Of Clinical Oncology 2023, 41: 10598-10598. DOI: 10.1200/jco.2023.41.16_suppl.10598.Peer-Reviewed Original ResearchDecisional conflictGenetic testingPre-test genetic counselingGermline testingGenetic counselingProstate cancerRandomized non-inferiority trialHereditary cancer risk assessmentGermline genetic testingClinical trial eligibilityNon-inferiority trialProstate Cancer FoundationProstate cancer managementCancer genetic testingDecision Conflict ScaleCancer risk assessmentGermline evaluationTrial eligibilityPrimary endpointMean ageStudy protocolCancer managementGenetics educationAnalysis of covarianceCancer Foundation
2022
Insight into how patients with prostate cancer interpret and communicate genetic test results: implications for families
Leader A, Mercado J, Klein A, Hyatt C, Gross L, Brandt R, Giri V. Insight into how patients with prostate cancer interpret and communicate genetic test results: implications for families. Journal Of Community Genetics 2022, 13: 547-556. PMID: 35869324, PMCID: PMC9681950, DOI: 10.1007/s12687-022-00603-1.Peer-Reviewed Original ResearchGenetic test resultsProstate cancerGenetic testingDiagnosis of PCaFamily membersClinical trial optionsGermline genetic testingPV/LPVRelevant family membersGenetic testing experiencesImmediate family membersPCa patientsCancer screeningPatientsTrial optionsPrecision therapyGenetic resultsGenetic counselorsTesting experienceThematic analysisCommunication barriersSemi-structured interviewsParticipantsTherapyTestingGenetic testing in prostate cancer management: Considerations informing primary care
Giri V, Morgan T, Morris D, Berchuck J, Hyatt C, Taplin M. Genetic testing in prostate cancer management: Considerations informing primary care. CA A Cancer Journal For Clinicians 2022, 72: 360-371. PMID: 35201622, DOI: 10.3322/caac.21720.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsNational Comprehensive Cancer Network guidelinesProstate cancerPrimary careGenetic testingNetwork guidelinesFamily historyClinical trial optionsGermline genetic testingMetastatic prostate cancerPrimary care providersMultidisciplinary patient careProstate cancer managementRole of cliniciansHereditary cancer riskMultiple professional societiesComprehensive family historyPC survivorsGermline testingPC screeningAggressive diseasePoor outcomePC careClinical pathwayCancer managementCancer risk
2021
Barriers and facilitators of germline genetic evaluation for prostate cancer.
Loeb S, Li R, Sanchez Nolasco T, Byrne N, Cheng H, Leader A, Giri V. Barriers and facilitators of germline genetic evaluation for prostate cancer. Journal Of Clinical Oncology 2021, 39: 28-28. DOI: 10.1200/jco.2021.39.6_suppl.28.Peer-Reviewed Original ResearchCoordination of careProstate cancerGenetic testingChronic Diseases frameworkGuideline-concordant careGermline genetic testingMetastatic prostate cancerGenetic counselingGermline testingLocalized diseasePatient factorsMedical oncologistsTherapeutic optionsCancer screeningPhysicians' knowledgeCurrent guidelinesPhysician educationRecent approvalRadiation oncologistsPractice settingsCancerDisease frameworkThematic saturationProstate Cancer GeneticsGenetic evaluation
2020
Practical Considerations and Challenges for Germline Genetic Testing in Patients With Prostate Cancer: Recommendations From the Germline Genetics Working Group of the PCCTC.
Szymaniak BM, Facchini LA, Giri VN, Antonarakis ES, Beer TM, Carlo MI, Danila DC, Dhawan M, George D, Graff JN, Gupta S, Heath E, Higano CS, Liu G, Molina AM, Paller CJ, Patnaik A, Petrylak DP, Reichert Z, Rettig MB, Ryan CJ, Taplin ME, Vinson J, Whang YE, Morgans AK, Cheng HH, McKay RR. Practical Considerations and Challenges for Germline Genetic Testing in Patients With Prostate Cancer: Recommendations From the Germline Genetics Working Group of the PCCTC. JCO Oncology Practice 2020, 16: 811-819. PMID: 32986533, PMCID: PMC7735040, DOI: 10.1200/op.20.00431.Peer-Reviewed Original ResearchConceptsGermline genetic testingProstate cancerGenetic testingNumber of patientsCritical unmet needCurrent guidelinesTesting deliveryPatientsUnmet needPrecision oncologyGenomic testingGenetic counselingGenetics providersGenetic servicesClinical workflowCancerOncologyLimited accessWorking GroupGuidelinesStandardized systemProvidersTestingClinic
2019
Germline Genetic Testing in Advanced Prostate Cancer; Practices and Barriers: Survey Results from the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium
Paller CJ, Antonarakis ES, Beer TM, Borno HT, Carlo MI, George DJ, Graff JN, Gupta S, Heath EI, Higano CS, McKay RR, Morgans AK, Patnaik A, Petrylak DP, Rettig MB, Ryan CJ, Taplin ME, Whang YE, Vinson J, Cheng HH, Giri VN, Group P. Germline Genetic Testing in Advanced Prostate Cancer; Practices and Barriers: Survey Results from the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium. Clinical Genitourinary Cancer 2019, 17: 275-282.e1. PMID: 31171481, PMCID: PMC6662206, DOI: 10.1016/j.clgc.2019.04.013.Peer-Reviewed Original ResearchConceptsProstate Cancer Clinical Trials ConsortiumGermline genetic testingClinical Trials ConsortiumGenetic testingPCa patientsAdvanced prostate cancer patientsAdvanced prostate cancerMetastatic PCa patientsClinical trial eligibilityProstate cancer patientsPan-cancer panelCancer gene panelTrial eligibilityChoice of assayLocal diseaseCancer CenterAcademic oncologistsCancer patientsProstate cancerCancer treatment facilitiesPatientsBusy clinicPrecision therapyPersonalized treatmentWorking Group
2018
Germline genetic testing for inherited prostate cancer in practice: Implications for genetic testing, precision therapy, and cascade testing
Giri V, Hegarty S, Hyatt C, O'Leary E, Garcia J, Knudsen K, Kelly W, Gomella L. Germline genetic testing for inherited prostate cancer in practice: Implications for genetic testing, precision therapy, and cascade testing. The Prostate 2018, 79: 333-339. PMID: 30450585, DOI: 10.1002/pros.23739.Peer-Reviewed Original ResearchConceptsBreast cancer family historyCancer family historyProstate cancerFamily historyMetastatic diseaseGleason scoreExact testGenetic testingRetrospective cross-sectional analysisDNA repair genesCurrent NCCN guidelinesInherited prostate cancerGermline genetic testingHigh Gleason scoreFisher's exact testIdentification of menRepair genesPathogenic variant spectrumCross-sectional analysisFamily history dataGenetic testing capabilitiesNCCN guidelinesTherapeutic managementMultigene testingPV ratesEvolving Intersection Between Inherited Cancer Genetics and Therapeutic Clinical Trials in Prostate Cancer: A White Paper From the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium.
Carlo M, Giri V, Paller C, Abida W, Alumkal J, Beer T, Beltran H, George D, Heath E, Higano C, McKay R, Morgans A, Patnaik A, Ryan C, Schaeffer E, Stadler W, Taplin M, Kauff N, Vinson J, Antonarakis E, Cheng H. Evolving Intersection Between Inherited Cancer Genetics and Therapeutic Clinical Trials in Prostate Cancer: A White Paper From the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium. JCO Precision Oncology 2018, 2018: 1-14. PMID: 30761386, PMCID: PMC6370313, DOI: 10.1200/po.18.00060.Peer-Reviewed Original ResearchGermline genetic testingProstate cancerGenetic testingAdvanced diseaseClinical trialsTreatment selectionProstate Cancer Clinical Trials ConsortiumClinical trial eligibility determinationCascade testingClinical Trials ConsortiumTherapeutic clinical trialsGenetic counselingClinical trial purposesTumor genomic profilingPost-test genetic counselingCancer risk assessmentDNA damage repair genesAppropriate genetic counselingTreatment response predictionWorking GroupClinical benefitPrompt testingCancer screeningGenetic testing practicesTreatment decisions